


## Key facts

	Females	Males	Total
<b>Number of new cases per year</b>	-	3,474	-
<b>Incidence rate (cases per 100,000 per year)</b>	-	141	-
<b>Cumulative lifetime risk of diagnosis (to age 74)</b>	-	1 in 8	-
<b>Percentage of all invasive cancers *</b>	-	29.2%	-
<b>Ranking among most common cancers *</b>	-	1 <sup>st</sup>	-
<b>Number of deaths per year</b>	-	519	-
<b>Mortality rate (deaths per 100,000 per year)</b>	-	22.2	-
<b>Cumulative lifetime risk of death (to age 74)</b>	-	1 in 115	-
<b>Percentage of all cancer deaths</b>	-	11%	-
<b>Ranking among most common invasive cancer deaths</b>	-	3 <sup>rd</sup>	-
<b>Number of people with this cancer still alive, end 2015 #</b>	-	32,555	-
<b>Number alive per 100,000</b>	-	1,421	-

\*invasive cases only, excluding non-melanoma skin cancer


# diagnosed since 1994

## Cases mapped by county



Annual average number of cases, 2005-2015:  
colours indicate higher or lower than expected  
based on national rates


## Age profile at diagnosis and death



## Top risk factors

- Family history of prostate cancer
  - Height/tallness
- Arsenic and arsenic compounds
- Cadmium and cadmium compounds

## Trend in incidence and mortality




APC<sup>#</sup> Incidence: (94-04) 7.5%, (04-11) 2.3%, (11-15) -4.3%

Mortality: (94-02) -0.3%, (02-15) -3.2%

# Annual Percentage Change

## Stage at diagnosis



## Treatment within 1 year

97%  
pathologically  
diagnosed

28% Surgery

28% Hormone  
therapy

36%  
Radiotherapy

% of all cases diagnosed 2013-2015

## 5 year net survival

Diagnosed	Net survival (age standardised)	95% confidence interval
1994-1998	65.8%	63.6-67.9%
1999-2003	82.3%	81.1-83.6%
2004-2008	91.0%	90.0-92.0%
2009-2013	91.5%	90.4-92.7%

\*10 year net survival (hybrid analysis):

88.7% (86.8-90.6%)